Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma

Journal of Thoracic Oncology

Volumn 11, Issue 12, 2016, Pages 2129-2140

  Li, Shiyong ^a   Choi, Yoon La ^b   Gong, Zhuolin ^a   Liu, Xiao ^a   Lira, Maruja ^c   Kan, Zhengyan ^c   Oh, Ensel ^b   Wang, Jian ^d   Ting, Jason C ^d   Ye, Xiangsheng ^d   Reinhart, Christoph ^d   Liu, Xiaoqiao ^e   Pei, Yunfei ^e   Zhou, Wei ^e   Chen, Ronghua ^e   Fu, Shijun ^f   Jin, Gang ^f   Jiang, Awei ^a   Fernandez, Julio ^c   Hardwick, James ^c   Kang, Min Woong ^g   Hoseok, I ^h   Zheng, Hancheng ^a   Kim, Jhingook ^b   Mao, Mao ^c   more..

^a BGI SHENZHEN   (China)

^b Samsung Medical Center   (South Korea)

^c PFIZER INC   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f Shanghai Biochip Co Ltd   (China)

^g Chungnam National University   (South Korea)

^h Pusan National University School of Medicine   (South Korea)

Author keywords

Adenocarcinoma; Asian; Driver genes; Lung cancer

Indexed keywords

ADULT; AGED; ALK GENE; ARTICLE; ASIAN; BRAF GENE; CANCER STAGING; CONTROLLED STUDY; EGFR GENE; ERBB2 GENE; EXON SKIPPING; FEMALE; GENE; GENE FUSION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MET GENE; MUTATION RATE; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RET; PREVALENCE; ROS1 GENE; SMOKING; ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOGENESIS; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOGENESIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 85010782754     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.08.142     Document Type: Article

References (49)

1. Kenfield SA, Wei EK, Stampfer MJ, , et al. Comparison of aspects of smoking among four histologic types of lung cancer. Tob Control. 2008;17:198-204.
2. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology. 2006;11:533-538.
3. Cheng YW, Chiou HL, Sheu GT, , et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res. 2001;61:2799-2803.
4. Le Calvez F, Mukeria A, Hunt JD, , et al. TP53, KRAS mutation load, types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, , current smokers. Cancer Res. 2005;65:5076-5083.
5. Kosaka T, Yatabe Y, Endoh H, , et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological, clinical implications. Cancer Res. 2004;64:8919-8923.
6. Sun Y, Ren Y, Fang Z, , et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010;28:4616-4620.
7. Soda M, Choi YL, Enomoto M, , et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.
8. Shaw AT, Yeap BY, Mino-Kenudson M, , et al. Clinical features, outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247-4253.
9. Takeuchi K, Soda M, Togashi Y, , et al. RET, ROS1, ALK fusions in lung cancer. Nat Med. 2012;18:378-381.
10. Bergethon K, Shaw AT, Ou SH, , et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-870.
11. Ju YS, Lee WC, Shin JY, , et al. A transforming KIF5B, RET gene fusion in lung adenocarcinoma revealed from whole-genome, transcriptome sequencing. Genome Res. 2012;22:436-445.
12. Vogelstein B, Papadopoulos N, Velculescu VE, , et al. Cancer genome landscapes. Science. 2013;339:1546-1558.
13. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543-550.
14. Ding L, Getz G, Wheeler DA, , et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069-1075.
15. Govindan R, Ding L, Griffith M, , et al. Genomic landscape of non-small cell lung cancer in smokers, neversmokers. Cell. 2012;150:1121-1134.
16. Imielinski M, Berger AH, Hammerman PS, , et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150:1107-1120.
17. Krishnan VG, Ebert PJ, Ting JC, , et al. Whole-genome sequencing of Asian lung cancers: second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers. Cancer Res. 2014;74:6071-6081.
18. Xiong D, Li G, Li K, , et al. Exome sequencing identifies MXRA5 as a novel cancer gene frequently mutated in non-small cell lung carcinoma from Chinese patients. Carcinogenesis. 2012;33:1797-1805.
19. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006;118:257-262.
20. Kan Z, Zheng H, Liu X, , et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23:1422-1433.
21. Wang K, Yuen ST, Xu J, , et al. Whole-genome sequencing, comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46: 573-582.
22. Lira ME, Choi YL, Lim SM, , et al. A single-tube multiplexed assay for detecting ALK, ROS1, , RET fusions in lung cancer. J Mol Diagn. 2014;16:229-243.
23. Li H, Durbin R. Fast, accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754-1760.
24. Beijing Genomics Institute. Short oligonucleotide analysis package. http://soap.genomics.org.cn/SOAPsnv. html. Accessed September 22, 2016.
25. Zhang ZD, Du J, Lam H, , et al. Identification of genomic indels, structural variations using split reads. BMC Genomics. 2011;12:375.
26. Chiang DY, Getz G, Jaffe DB, , et al. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods. 2009;6:99-103.
27. Beroukhim R, Getz G, Nghiemphu L, , et al. Assessing the significance of chromosomal aberrations in cancer: methodology, application to glioma. Proc Natl Acad Sci USA. 2007;104:20007-20012.
28. Wang J, Mullighan CG, Easton J, , et al. CREST maps somatic structural variation in cancer genomes with basepair resolution. Nat Methods. 2011;8:652-654.
29. Jia P, Pao W, Zhao Z. Patterns, processes of somatic mutations in nine major cancers. BMC Med Genomics. 2014;7:11.
30. Kandoth C, McLellan MD, Vandin F, , et al. Mutational landscape, significance across 12 major cancer types. Nature. 2013;502:333-339.
31. Alexandrov LB, Nik-Zainal S, Wedge DC, , et al. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013;3:246-259.
32. Nik-Zainal S, Alexandrov LB, Wedge DC, , et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149:979-993.
33. Stransky N, Cerami E, Schalm S, , et al. The landscape of kinase fusions in cancer. Nat Commun. 2014;5: 4846.
34. Youn A, Simon R. Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics. 2011;27:175-181.
35. Arcila ME, Chaft JE, Nafa K, , et al. Prevalence, clinicopathologic associations, , molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18:4910-4918.
36. Pan Y, Zhang Y, Li Y, , et al. Prevalence, clinicopathologic characteristics, , molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. Ann Surg Oncol. 2014;21(suppl 4): S490-S496.
37. Arcila ME, Nafa K, Chaft JE, , et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, , clinicopathologic characteristics. Mol Cancer Ther. 2013;12:220-229.
38. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data, clinical implications. Lancet Oncol. 2012;13: e23-e31.
39. Xu W, Soga S, Beebe K, , et al. Sensitivity of epidermal growth factor receptor, ErbB2 exon 20 insertion mutants to Hsp90 inhibition. Brit J Cancer. 2007;97:741-744.
40. Kong-Beltran M, Seshagiri S, Zha J, , et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006;66:283-289.
41. Zhang YW, Staal B, Essenburg C, , et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 2010;70:6880-6890.
42. Frampton GM, Ali SM, Rosenzweig M, , et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types, confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5:850-859.
43. Jenkins RW, Oxnard GR, Elkin S, , et al. Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. Clin Lung Cancer. 2015;16: e101-e104.
44. Cardarella S, Ogino A, Nishino M, , et al. Clinical, pathologic, , biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19:4532-4540.
45. Gautschi O, Pauli C, Strobel K, , et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol. 2012;7:e23-e24.
46. Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol. 2013;8:e41-e42.
47. Thun MJ, Hannan LM, Adams-Campbell LL, , et al. Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts, 22 Cancer Registry Studies. PLoS Med. 2008;5:e185.
48. Mok TS, Wu YL, Thongprasert S, , et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
49. Mazieres J, Zalcman G, Crino L, , et al. Crizotinib therapy for advanced lung adenocarcinoma, a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-999.